BioCryst Receives a Buy from FBR Capital

By Jason Carr

FBR Capital analyst Christopher James reiterated a Buy rating on BioCryst (NASDAQ: BCRX) yesterday and set a price target of $6. The company’s shares opened today at $4.67.

James observed:

“On the morning of November 7, BioCryst Pharmaceuticals hosted a conference call to discuss its 3Q16 financial performance and to provide an update on the developmental progress of BCX7353, an oral kallikrein inhibitor for the prophylactic treatment of HAE attacks. In 4Q16 and throughout 2017, we expect BioCryst to remain focused on the Phase II APeX-1 study of BCX7353. As of November 4, a total of 19 and 16 patients had been screened and randomized, respectively. Based on the current projections for screening and randomization, the expected data readout from Part 1 of APeX-1 should be in 1Q17 (previous guidance was by the end of 2016). We remind investors that BCX4430 has completed Phase I development with an intramuscular injection (im) formulation, which has demonstrated broad spectrum viral activity, including preclinical activity in the Ebola and Zika viruses.”

According to, James is ranked 0 out of 5 stars with an average return of -22.7% and a 23.9% success rate. James covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Inc., Aviragen Therapeutics, Inc., and Achillion Pharmaceuticals.

BioCryst has an analyst consensus of Strong Buy.

Based on BioCryst’s latest earnings report from June 30, the company posted quarterly revenue of $4.79M and quarterly net profit of -$16.28M. In comparison, last year the company earned revenue of $10.99M and had a net profit of -$14.62M.

Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is negative on the stock. Most recently, in August 2016, Yarlagadda Babu, the SVP – Drug Discovery of BCRX sold 30,000 shares for a total of $121,800.

BioCryst Pharmaceuticals, Inc. is a biotechnology company, which designs, optimizes and develops novel drugs that block key enzymes involved in the pathogenesis of diseases with its focus on therapeutic areas with unmet medical needs. It integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. The company was founded in 1986 and is headquartered in Birmingham, AL.